Compare IGIC & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | WGS |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2019 | 2020 |
| Metric | IGIC | WGS |
|---|---|---|
| Price | $27.00 | $78.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $28.00 | ★ $120.71 |
| AVG Volume (30 Days) | 98.5K | ★ 803.4K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 62.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $427,539,000.00 |
| Revenue This Year | $0.13 | $29.98 |
| Revenue Next Year | $2.54 | $25.92 |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | ★ 39.97 |
| 52 Week Low | $20.82 | $32.21 |
| 52 Week High | $29.59 | $170.87 |
| Indicator | IGIC | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 62.33 |
| Support Level | $26.81 | $56.36 |
| Resistance Level | $27.27 | $96.34 |
| Average True Range (ATR) | 0.82 | 6.02 |
| MACD | -0.21 | 1.46 |
| Stochastic Oscillator | 23.63 | 76.45 |
International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.